Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Core Viewpoint - Pfizer's experimental drug combination significantly reduces the risk of disease progression or death in breast cancer patients by 40% in a mid-stage trial [1][2]. Group 1: Drug Details - The combination of atirmociclib and fulvestrant was tested in patients with advanced breast cancer who had previously received treatment [2]. - The study compared the experimental drug combination to fulvestrant or everolimus plus exemestane, a common therapy for postmenopausal women with breast cancer [2]. - Over 90% of patients began treatment with atirmociclib within three months of stopping their previous cancer medication [3]. Group 2: Safety and Efficacy - The safety profile of atirmociclib was manageable, with only 6.4% of patients discontinuing treatment due to side effects [3]. - Overall survival data, which is a secondary goal of the study, is still in early stages and not yet conclusive [3]. Group 3: Future Plans - Pfizer plans to test atirmociclib in first-line and early-stage breast cancer to achieve longer-lasting disease control [4]. - A large late-stage study of atirmociclib in newly diagnosed metastatic breast cancer patients is already in progress [4].